Attendee search 

BioInvent is a research-based pharmaceutical company developing innovative antibody drugs to target diseases with unmet clinical need. The Company's pipeline currently includes three product candidates for the treatment of cancer.

Our mission is to generate value for shareholders by building a sustainable portfolio of clinical development projects and, over time, successfully launching several innovative drugs.

In order to maximise the value of the Company we plan to:

• Commercialise product candidates in co-operation with partners.
• Retain rights to individual geographic markets for particular products where we consider that it would be feasible to establish a competitive sales and marketing force.
• Broaden and expand our product portfolio to create more opportunities for generating successful products and increasing the likelihood of commercial success for the Company as a whole.
• Gain access to innovative target proteins and/or projects from external research groups and use these as a basis for generating novel therapeutics using our proprietary technology platform.

Our revenues include licence fees, milestone payments, compensation of manufacturing and royalties on sales derived from our co-operation agreements around our product candidates. We also generate income by providing discovery development to our customers.

We expect to achieve sustainable profitability as soon as one of our products reaches the market. However, profits may be reported in certain years before this as projects reach key milestones that trigger payments from partners.

Because of restricted inherent capacity of regeneration and healing, the restoration of function to damaged heart remains formidable contest. In our laboratory we are trying to develop protocols for regenerating pig heart tissues by first stripping of cells and then repopulating the acellular scaffold with human stem cells. Such tissue engineered hearts may be potentially used for transplantation in future.